ACAD ACADIA Pharmaceuticals Inc.
Healthcare$21.10-1.03%ClosedMarket Cap: $3.61B
As of 2026-05-25
Valuation
P/E (TTM)
9.48
PEG
0.13
P/B
2.88
P/S
3.30
EV/EBITDA
32.34
DCF Value
$-37.33
FCF Yield
5.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.5%
Operating Margin
7.4%
Net Margin
34.3%
ROE
35.6%
ROA
23.4%
ROIC
6.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $268.1M | 90.8% | $-4.6M | $3.6M | $— | — |
| Q4 null | $284.0M | 90.8% | $17.4M | $273.6M | $— | — |
| FY null | $1.07B | 91.7% | $104.8M | $391.0M | $— | — |
| Q3 null | $278.6M | 92.2% | $35.8M | $71.8M | $— | — |
| Q2 null | $264.6M | 92.2% | $32.4M | $26.7M | $— | — |
| Q1 null | $244.3M | 91.7% | $19.3M | $19.0M | $— | — |
| Q4 null | $259.6M | 91.6% | $153.5M | $143.7M | $— | — |
| FY null | $957.8M | 91.5% | $230.8M | $226.5M | $— | — |
| Q3 null | $250.4M | 92.5% | $31.6M | $32.8M | $— | — |
| Q2 null | $242.0M | 92.5% | $30.4M | $33.4M | $— | — |
| Q1 null | $205.8M | 88.8% | $15.2M | $16.6M | $— | — |
| Q4 2023 | $231.0M | 92.3% | $34.9M | $45.8M | $0.28 | — |